Greenleaf Trust Purchases 16,267 Shares of Pfizer Inc. (NYSE:PFE)

Greenleaf Trust grew its position in Pfizer Inc. (NYSE:PFE - Free Report) by 6.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 252,749 shares of the biopharmaceutical company's stock after purchasing an additional 16,267 shares during the quarter. Greenleaf Trust's holdings in Pfizer were worth $6,405,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of PFE. CORDA Investment Management LLC. boosted its position in shares of Pfizer by 5.8% during the first quarter. CORDA Investment Management LLC. now owns 1,075,063 shares of the biopharmaceutical company's stock worth $27,242,000 after acquiring an additional 59,047 shares during the last quarter. New Insight Wealth Advisors bought a new position in shares of Pfizer during the first quarter worth $3,450,000. OMNI 360 Wealth Inc. boosted its position in shares of Pfizer by 7.4% during the first quarter. OMNI 360 Wealth Inc. now owns 10,979 shares of the biopharmaceutical company's stock worth $278,000 after acquiring an additional 753 shares during the last quarter. 49 Wealth Management LLC boosted its position in shares of Pfizer by 54.5% during the first quarter. 49 Wealth Management LLC now owns 13,141 shares of the biopharmaceutical company's stock worth $333,000 after acquiring an additional 4,635 shares during the last quarter. Finally, Stratos Wealth Advisors LLC boosted its position in shares of Pfizer by 35.6% during the first quarter. Stratos Wealth Advisors LLC now owns 71,949 shares of the biopharmaceutical company's stock worth $1,823,000 after acquiring an additional 18,900 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Citigroup upped their target price on shares of Pfizer from $23.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. BMO Capital Markets dropped their target price on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. The Goldman Sachs Group upped their target price on shares of Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. HSBC decreased their price target on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. Finally, Leerink Partners decreased their price target on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $28.55.

Pfizer Stock Performance

Shares of PFE opened at $25.61 on Wednesday. The stock has a 50 day moving average price of $23.80 and a 200 day moving average price of $24.81. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $145.60 billion, a price-to-earnings ratio of 18.56, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the prior year, the company earned $0.82 earnings per share. The company's revenue was down 7.8% compared to the same quarter last year. Research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.72%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.